CONNECT WITH US

Have questions about longevity research, anti-aging interventions, or healthy lifestyle strategies? Our team of medical and scientific experts is here to help you navigate the complex world of aging science. Whether you’re curious about the latest supplement studies, wondering about emerging longevity technologies, or seeking evidence-based guidance on preventive health measures, we’re committed to providing you with thoroughly researched, unbiased answers. No question is too complex, too basic, or too niche—we believe every inquiry deserves a science-backed response.

 

Business statement: Interested in partnerships, media collaborations, or affiliations? We’d love to connect.

Reach out email: business@email.com

Customer Form

Colton

Colton Qiu, PhD

Editor-in-Chief, Scientific Research

Colton is a regenerative medicine scientist with a focus on transfusion science, stem cell engineering, and platelet-based therapies. He earned his PhD in Medicine from Kyoto University’s Center for iPS Cell Research and Application (CiRA), the pioneering institute behind induced pluripotent stem cell (iPSC) technology. His research centered on improving the biomanufacturing process and long-term preservation of iPSC-derived platelets, advancing their applications in both transfusion medicine and next-generation PRP (platelet-rich plasma) therapies for tissue regeneration.

Beyond the lab, Colton is the co-founder and former president of the Japan–Taiwan Biotechnology Association (JTBA), where he played a pivotal role in establishing high-impact collaborations between academia, industry, and government to foster regenerative medicine innovation across Asia. He completed his doctoral training with the support of the Japan–Taiwan Exchange Association Scholarship, awarded for his outstanding contributions to cross-cultural scientific advancement.

Since completing his PhD, Colton has turned his focus toward the future of personalized healthcare. He firmly believes that science-backed strategies to delay aging and enhance healthspan already exist—but they must be tailored to each individual. Rejecting the idea of a “one-size-fits-all” solution, he advocates for making personalized longevity planning both scientifically rigorous and economically accessible. His mission is to help more people design evidence-based, customized pathways to healthier, longer lives.

Right down 2
Tristan

Tristan Yeung, MD

Editor-in-Chief, Medical Research

Tristan brings a distinctive perspective to longevity research through his integration of clinical medicine, translational research, and biomedical innovation. His MD from Harvard Medical School, combined with extensive engagement with Harvard Innovation Lab and HMS Makerspace, reflects his commitment to transforming scientific discoveries into practical interventions that can extend healthy human lifespan. His internal medicine internship at California Pacific Medical Center provides him with frontline clinical experience in treating age-related diseases, giving him intimate knowledge of how aging manifests in real patients and what interventions might have the greatest impact on healthspan extension.

Tristan’s translational research at Stanford’s Department of Radiology and Canary Center, where he implemented novel microRNA-encapsulated nanoparticle drug delivery systems for localized cancer treatment, demonstrates his expertise in cutting-edge therapeutic delivery mechanisms increasingly relevant to anti-aging interventions. His bioengineering background from Stanford University, where he developed a vitamin-eluting subdermal implantable rod for nutritional deficiencies as a Terman Engineering Scholar, showcases his innovative approach to sustained therapeutic delivery – a critical consideration for longevity interventions that must work over extended timeframes. Tristan’s unique combination of clinical training, research expertise, and entrepreneurial vision enables him to identify which longevity interventions hold promise for extending not just lifespan, but healthspan.

Right down 2
Jean cruz

Jean Cruz-Hernandez, PhD

Scientific Advisor

Jean Cruz (JC) combines deep scientific rigor with strategic vision as Global Managing Partner of AGMI, bringing a rare blend of bench science expertise and commercial acumen to longevity research analysis. His PhD in Biomedical Engineering from Cornell University, coupled with a postdoctoral fellowship and junior faculty position at Massachusetts General Hospital and Harvard Medical School, provides him with the technical depth needed to evaluate complex longevity interventions with scientific precision. JC’s pioneering work in neurodegenerative diagnostic and imaging platforms during his academic career gives him unique insight into one of aging’s most devastating aspects – cognitive decline, while his research that produced several US patents, over $5 million in sponsored grants, and publications in Nature demonstrates his ability to identify breakthrough approaches that could revolutionize how we understand aging processes. His specialized research initiatives focused on understanding aging-related neurological decline and developing therapeutic interventions position him at the forefront of one of longevity science’s most critical frontiers.

His extensive experience at McKinsey & Company, where he led strategic transformations for Fortune 500 pharma companies and conducted due diligence across oncology, neuroscience, and rare-disease portfolios, equips him to navigate the complex landscape of longevity research with both scientific rigor and commercial insight. JC’s work positions him to identify which approaches have genuine therapeutic potential versus those destined for clinical failure. JC brings unparalleled expertise in translating cutting-edge aging research into practical strategies that can extend healthy human aging.

Right down 2
Harvey

Yen-Po (Harvey) Chin, MD, PhD

Medical Advisor and Strategy Lead

Harvey brings a unique convergence of clinical medicine, bioinformatics, and advanced analytics to the pursuit of longevity science, combining deep scientific training with strategic vision to advance anti-aging research. His medical training from National Yang Ming Chiao Tung University and his PhD in Biomedical Informatics from Taipei Medical University, coupled with his postdoctoral Master of Biomedical Informatics from Harvard Medical School, positions him uniquely at the intersection where cutting-edge longevity research meets computational analysis and practical implementation. As a physician turned entrepreneur, Harvey understands both the clinical realities of aging-related diseases and the technological possibilities for intervention, giving him rare insight into how breakthrough biomedical innovations can translate from laboratory discoveries to meaningful patient outcomes.

As a Forbes 30 Under 30 honoree and Harvard Healthtech Innovation Fellow, Harvey has consistently identified and championed emerging technologies before they reach mainstream adoption, a skill directly applicable to the rapidly evolving field of longevity research. His experience as Executive Chairman of AGMI Group, where he has orchestrated over $1.5 billion in potential value through strategic partnerships in biopharma and advanced technology enterprises, demonstrates his ability to discern which medical interventions hold genuine therapeutic promise versus those destined for clinical failure. His frequent speaking engagements at Harvard, MIT, BIO Asia Conference, and Academia Sinica position him to stay at the forefront of longevity research developments as they emerge from the world’s leading institutions, while his commitment to developing the next generation of leaders through the AAC Talent Hub reflects his dedication to ensuring breakthrough anti-aging discoveries benefit future generations.

Right down 2

Longevity, Delivered to Your Inbox

Subscribe for curated research updates, practical tips, and the latest anti-aging breakthroughs

Subscription Form